Silence Therapeutics has appointed Dave Lemus to its Board as non-executive director and Richard Jenkins as head of clinical development. Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. He is currently executive vice chair, chief operating officer and CFO of Proteros biostructures. He also currently serves as a non-executive board member of BioHealth Innovation, Sorrento Therapeutics, and the MIT Club of Washington DC.
{iframe}http://www.pharmatimes.com/appointments/silence_therapeutics_strengthens_board_and_leadership_team_1241121{/iframe}